New drug aims to limit heart attack damage in early trial
NCT ID NCT07091929
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new medicine called SGC001 in 38 people having a heart attack procedure. The goal was to see if it is safe and might reduce heart muscle damage and inflammation. Participants received either the drug or a placebo by IV once. The drug is not yet approved anywhere.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTERIOR MYOCARDIAL INFARCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Anzhen Hospital Capital Medical University
Beijing, Beijing Municipality, 100013, China
-
Linfen Central Hospital
Linfen, Shanxi, 041099, China
-
Teda International Cardiovascular Hospital
Tianjin, Tianjin Municipality, 300457, China
-
The 2nd Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, 150086, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.